October 30, 2012

$PVCT.OB: Early Majority

Where does management believe PV-10 currently resides regarding the view of the drug by key opinion leaders and the medical community? Early Majority.

In 2011, before Moffitt researchers were paid by Provectus for their pre-clinical work, Moffitt conducted its own unsponsored work on PV-10's immune response. Researchers, following their reproduction of Craig and the team's work, identification of PV-10's quintessential immune response, and the broader and deeper follow-up work, purportedly said (paraphrasing): "We know our place in history."

In 2012, Steven Koevary, Biomedical Sciences and Disease, New England College of Optometry and Department of Cell Biology, University of Massachusetts Medical School, concluded rose bengal (PV-10) may not only suppress ovarian cancer cell growth but also induce their apoptotic cell death, justifying the further investigation of the effects of RB in an animal model of ovarian cancer. He also noted "Thus, even when optimally debulked, many patients still exhibit tumor nodules too small to have been resected by even the most skilled surgeon that likely seed future growths. In light of the above data, it is theorized that injection of these nodules with RB at the time of surgery may prove to be an effective strategy for not only their elimination, but for vaccinating patients against the future regrowth of gross tumors. This notion is supported by data that showed that PV-10 treatment increased the levels of tumor infiltrating lymphocytes and that the overall survival of ovarian cancer patients was greater in patients whose tumors contained T cells." This blog post is here.

It is rumored unsponsored PV-10 pre-clinical work is being done at Rockefeller University, which, interestingly enough, is the first institution in the U.S. devoted to biomedical research. It is rumored several other institutions inside and outside the U.S. are also conducting unsponsored pre-clinical work.

No comments:

Post a Comment